Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1711754 · FYE Dec 31 · Prices AT CLOSE 2026-07-28 (USD) — end-of-day, never a live or intraday quote
Last $1.71Day −1.16%Mkt cap $45M1Y −41.2%Off 52W high −47.3%Vol (1Y) 76.0%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,875 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest9.0% of sh out |
| Days to cover2.2d |
| 13F net flow (QoQ)+1.27% |
| Top-10 13F concentration74.5% |
| Next report (est.)2026-08-01 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$50,000 |
| Earnings (TTM)-$41.6M |
| ROE−165.2% |
| Net margin−91866.0% |
| Sales growth 3Y−48.9% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+9.6% |
| 1Y−41.2% |
| 3Y−79.7% |
| 5Y−90.5% |
| Since incept. (ann.)−18.6% |
Total return through 2026-07-28 · series begins 2019-02-04. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)76.0% |
| Ann. volatility (3Y)87.3% |
| Sharpe (1Y)−0.34 |
| Sharpe (3Y)−0.14 |
| Max drawdown (1Y)−64.6% |
| Max drawdown (3Y)−92.0% |
| Beta (3Y vs SPY)0.91 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| BlackRock, Inc. | 1.2M | $1M | 4.49% | −1.5% |
| VANGUARD CAPITAL MANAGEMENT LLC | 687,015 | $776,327 | 2.58% | new |
| GEODE CAPITAL MANAGEMENT, LLC | 494,969 | $559,464 | 1.86% | +12.1% |
| STATE STREET CORP | 290,879 | $328,693 | 1.09% | −16.2% |
| AQR CAPITAL MANAGEMENT LLC | 270,317 | $305,458 | 1.02% | +1217.4% |
| UBS Group AG | 253,340 | $286,274 | 0.95% | +316.7% |
| GOLDMAN SACHS GROUP INC | 231,586 | $261,692 | 0.87% | +310.1% |
| RAYMOND JAMES FINANCIAL INC | 203,245 | $229,667 | 0.76% | −3.5% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | −$0.20 | — | — | — |
| 2025-09-30 | 2025-10-30 | −$0.24 | — | — | — |
| 2025-06-30 | 2025-08-07 | −$1.05 | — | — | — |
| 2025-03-31 | 2025-05-08 | −$0.43 | — | $50,000 | +257.1% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-01 is ESTIMATED from filing cadence (median gap 86d) — not company-confirmed.
